Study analysis · Clinical & Experimental Metastasis · 2018
A common heart drug just got a new job: stopping breast cancer from spreading?
A drug used to prevent heart attacks, called ticagrelor, helped stop breast cancer from spreading to the lungs in mice, but a similar drug did not.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in mice and in lab dishes, not in people. It shows that ticagrelor, a drug used for heart disease, helped stop cancer from spreading in mice. But we don't know if it would do the same in humans—it's like testing a new recipe on a small group of friends; you need to try it on many more people to be sure.
What’s the bottom line?
This study looked at whether ticagrelor, a drug used to prevent heart attacks, can stop breast cancer from spreading to other organs.
How strong is this study?
The study had a control group and looked at important things like how much cancer spread and how long mice lived. But we don't know if the researchers were 'blinded' (not knowing which mice got the drug) or if the mice were randomly assigned to groups. That means the study might not be as reliable as a well-designed human trial.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal and in vitro study, not a human clinical trial. Causation cannot be established for humans. While the animal model suggests a potential mechanism, human studies are required to confirm any causal relationship.
COI Unknown
Could not determine conflict of interest status
No conflict of interest information is provided in the available text.
Only abstract is available; full text may contain declarations.
Key takeaways
- 01
In mice with breast cancer, ticagrelor reduced the spread of cancer to the lungs and helped them live longer.
- 02
Another similar drug, clopidogrel, did not have the same effect.
- 03
This is promising but only tested in mice and in lab dishes, so we don't yet know if it works in people.
Surprising findings
- Clopidogrel, an irreversible P2Y12 inhibitor, did not reduce metastasis or improve survival, while ticagrelor did.Both target the same receptor, so one would expect similar effects. This suggests ticagrelor may have unique mechanisms beyond P2Y12 inhibition.
- Ticagrelor did not enhance natural killer (NK) cell killing of cancer cells, contrary to the hypothesis that platelet shielding protects from immune surveillance.It was assumed that blocking platelets would unleash immune cells, but this study showed no improvement in NK cell activity, indicating a different mechanism.
- Ticagrelor had no effect on primary tumor growth in mice, only on metastasis.Many assume an anti-cancer drug would shrink tumors; this shows metastasis can be targeted separately from primary tumor growth.
Practical takeaways
Patients with breast cancer should NOT take ticagrelor based on this study alone; human trials are needed.
This is preclinical data in mice; effects in humans may differ, and ticagrelor has side effects like bleeding risk.
low confidenceFor researchers, this supports exploring P2Y12 inhibition as a target for metastasis prevention, especially with reversible inhibitors like ticagrelor.
The study only used one mouse model and a few cell lines; broader validation is required.
medium confidenceWhy this study matters
Heart Drug vs. Cancer
Ticagrelor, a P2Y12 inhibitor used for heart attack prevention, reduced lung metastasis and improved survival in a mouse model of breast cancer. In the study, mice treated with ticagrelor had fewer tumor cell-platelet aggregates in their lungs and lived longer than those given clopidogrel or saline.
This is a completely new use for a drug millions already take, potentially offering a cheap, safe way to prevent cancer spread if proven in humans.
The Clopidogrel Mystery
Surprisingly, clopidogrel (another P2Y12 inhibitor) did not reduce metastasis, even though it targets the same receptor. This suggests ticagrelor's unique binding kinetics or off-target effects may be key.
It challenges the assumption that all drugs in a class work the same way, opening up questions about repurposing specific drugs versus whole classes.
Not Shrinking Tumors, but Stopping Seeds
Ticagrelor did not affect primary tumor growth or cancer cell proliferation. Instead, it prevented early steps of metastasis by blocking platelets from clumping with tumor cells in the lungs.
This shifts focus from killing tumors to stopping their spread, a concept many people don't realize is different from shrinking primary tumors.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether ticagrelor, a drug used to prevent heart attacks, can stop breast cancer from spreading to other organs.
Research results
In mice with breast cancer, ticagrelor reduced the spread of cancer to the lungs and helped them live longer. Another similar drug, clopidogrel, did not have the same effect.
What this means - more context
This is promising but only tested in mice and in lab dishes, so we don't yet know if it works in people.
To determine if the P2Y12 inhibitor ticagrelor reduces tumor growth and metastasis in breast cancer.
Ticagrelor reduced platelet-tumor cell interactions in vitro and decreased lung metastasis and improved survival in a mouse model of breast cancer, while clopidogrel did not.
Methods Used
In vitro co-culture of human breast cancer cells with ticagrelor-treated platelets; orthotopic 4T1 mouse model with ticagrelor, clopidogrel, or saline treatment.
Main Finding
Ticagrelor (10 mg/kg) reduced lung metastasis and improved survival in mice, associated with reduced tumor cell-platelet aggregates in lungs.
Confidence Level
Moderate (preclinical data, not yet validated in humans)
Study Flags
Red Flags
- •Only tested in a single mouse model (4T1) and a few human cell lines
- •No human clinical data; effects may differ in patients
- •Possible off-target effects of ticagrelor not fully explored
Surprising Findings
Clopidogrel, an irreversible P2Y12 inhibitor, did not reduce metastasis or improve survival, while ticagrelor did.
Both target the same receptor, so one would expect similar effects. This suggests ticagrelor may have unique mechanisms beyond P2Y12 inhibition.
Practical Takeaways
Patients with breast cancer should NOT take ticagrelor based on this study alone; human trials are needed.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study was done in mice and in lab dishes, not in people. It shows that ticagrelor, a drug used for heart disease, helped stop cancer from spreading in mice. But we don't know if it would do the same in humans—it's like testing a new recipe on a small group of friends; you need to try it on many more people to be sure.
Strengths
- Multiple human breast cancer cell lines tested in vitro
- In vivo orthotopic mouse model with metastasis and survival endpoints
- Included control groups (saline and clopidogrel)
Weaknesses
- Animal model only, no human subjects
- Sample size not reported; likely small
- Randomization and blinding not described (unknown if performed)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether ticagrelor, a drug used to prevent heart attacks, can stop breast cancer from spreading to other organs.
Research results
In mice with breast cancer, ticagrelor reduced the spread of cancer to the lungs and helped them live longer. Another similar drug, clopidogrel, did not have the same effect.
What this means - more context
This is promising but only tested in mice and in lab dishes, so we don't yet know if it works in people.
To determine if the P2Y12 inhibitor ticagrelor reduces tumor growth and metastasis in breast cancer.
Ticagrelor reduced platelet-tumor cell interactions in vitro and decreased lung metastasis and improved survival in a mouse model of breast cancer, while clopidogrel did not.
Methods Used
In vitro co-culture of human breast cancer cells with ticagrelor-treated platelets; orthotopic 4T1 mouse model with ticagrelor, clopidogrel, or saline treatment.
Main Finding
Ticagrelor (10 mg/kg) reduced lung metastasis and improved survival in mice, associated with reduced tumor cell-platelet aggregates in lungs.
Confidence Level
Moderate (preclinical data, not yet validated in humans)
Study Flags
Red Flags
- •Only tested in a single mouse model (4T1) and a few human cell lines
- •No human clinical data; effects may differ in patients
- •Possible off-target effects of ticagrelor not fully explored
Surprising Findings
Clopidogrel, an irreversible P2Y12 inhibitor, did not reduce metastasis or improve survival, while ticagrelor did.
Both target the same receptor, so one would expect similar effects. This suggests ticagrelor may have unique mechanisms beyond P2Y12 inhibition.
Practical Takeaways
Patients with breast cancer should NOT take ticagrelor based on this study alone; human trials are needed.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study was done in mice and in lab dishes, not in people. It shows that ticagrelor, a drug used for heart disease, helped stop cancer from spreading in mice. But we don't know if it would do the same in humans—it's like testing a new recipe on a small group of friends; you need to try it on many more people to be sure.
Strengths
- Multiple human breast cancer cell lines tested in vitro
- In vivo orthotopic mouse model with metastasis and survival endpoints
- Included control groups (saline and clopidogrel)
Weaknesses
- Animal model only, no human subjects
- Sample size not reported; likely small
- Randomization and blinding not described (unknown if performed)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study had a control group and looked at important things like how much cancer spread and how long mice lived. But we don't know if the researchers were 'blinded' (not knowing which mice got the drug) or if the mice were randomly assigned to groups. That means the study might not be as reliable as a well-designed human trial.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal and in vitro study, not a human clinical trial. Causation cannot be established for humans. While the animal model suggests a potential mechanism, human studies are required to confirm any causal relationship.
COI Unknown
Could not determine conflict of interest status
No conflict of interest information is provided in the available text.
Only abstract is available; full text may contain declarations.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr. William Wallace cite this study, drawing 1 claim from it.
- Indication only
Weak evidence — fewer than 20 studies, so treat this as a starting point, not a fact.
Evidence